Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ANL vs TYRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 4–4 Matrix Metrics)

ANL Overall Winner 6-Pillar Tally: ANL 4 – 1 TYRA (1 Tie) Matrix Metrics: ANL 4 – 4 TYRA

As of Nov 16, 2026, ANL (ANL) is the stronger overall head-to-head candidate over Tyra Biosciences, Inc. (TYRA) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ANL carries a Unified Composite Score of 48.3/100 (HOLD) at $9.97 (N/M Forward P/E, -123.5% operating margin), whereas TYRA carries 33.0/100 (SELL) at $19.77 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: ANL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.0); meanwhile TYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANL vs TYRA
ANL US Equity Head-to-Head Winner
ANL
Institutional Equity
$9.97
-6.03% 1D
Market Cap $677.5M
TTM Revenue $18M
Forward P/E N/M
Beta / 30D Vol 2.61β · 79% Vol
Unified Composite Score
48.3 / 100 HOLD
Tech 48.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 44
RSI-14: 44.0 · SMA20: $10.32 · SMA50: $12.93
TYRA NASDAQ
Tyra Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$19.77
-1.27% 1D
Market Cap $1.3B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.79β · 49% Vol
Unified Composite Score
33.0 / 100 SELL
Tech 25.0 Fund 46.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.3%), weak momentum, RSI 43
RSI-14: 42.7 · SMA20: $20.95 · SMA50: $21.58

6-Pillar Scorecard Institutional Category Breakdown (ANL 4 – 1 TYRA)

Columns: Metric · ANL · TYRA
1. Valuation Multiples ANL
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 37.5x N/M
2. Growth & Scale ANL
Revenue Growth (YoY) +178.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $18M N/A
Market Cap $677.5M $1.3B
3. Profitability & Quality TYRA
Gross Margin 100.0% N/A
Operating Margin -123.5% 0.0%
Net Profit Margin -124.8% 0.0%
Return on Equity (ROE) -20.2% -34.9%
4. Balance Sheet & Cash Flow ANL
Cash Generation (TTM) -$22M EBITDA -$120M
Cash Flow Margin -119.9% EBITDA Mgn N/A
Net Cash / Leverage $3.34 Book/Sh · -20.2% ROE $451M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANL
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 69.0% (3rd %ile)
Put/Call OI Skew N/A 12.00x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANL (4) vs TYRA (4)
Institutional Metric ANL TYRA Criterion Row Edge
Market Capitalization
Scale
$677.5M $1.3B Larger Scale TYRA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+178.1% +0.0% Higher Growth ANL
Operating Margin (TTM)
Profitability
-123.5% 0.0% Higher Margin TYRA
Net Profit Margin
Profitability
-124.8% 0.0% Higher Margin TYRA
Return on Equity (ROE)
Capital Efficiency
-20.2% -34.9% Higher ROE ANL
52-Week Range Position
Momentum
56% ($1–$17) 20% ($15–$41) Stronger Trend ANL
Beta / 30D Volatility
Risk Regime
2.61β · 79% Vol 0.79β · 49% Vol Lower Realized Risk TYRA
Unified Institutional Score
Composite Signal
48.3 / 100 (HOLD) 33.0 / 100 (SELL) Higher Composite ANL
Trailing 12M Revenue (USD)
Operating Scale
$18M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 37.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$22M EBITDA ($3.34 Book/Sh · -20.2% ROE) -$120M ($451M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TYRA +16.36 pp
ANL: -9.61% · TYRA: +6.75%
3M Horizon TYRA +5.51 pp
ANL: -29.59% · TYRA: -24.08%
6M Horizon ANL +30.43 pp
ANL: -14.13% · TYRA: -44.56%
1Y Horizon ANL +533.45 pp
ANL: +560.26% · TYRA: +26.81%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANL vs TYRA. Trailing 12-month operating profitability (ANL -123.5% vs TYRA 0.0%) and valuation multiples (ANL N/M vs TYRA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ANL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$18M
Gross Margin100.0%
Op. Margin-123.5%
ROE / Fwd P/E-20.2% · N/M
TYRA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ANL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TYRA BREAKDOWN
76d in phase · OBV DISTRIBUTION
Current IV 69.0%
IV Percentile 3rd %ile
Put/Call OI Skew 12.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and -123.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANL vs TYRA Key Questions & Quantitative Answers

As of Nov 16, 2026, ANL (ANL) is the stronger overall head-to-head candidate over Tyra Biosciences, Inc. (TYRA) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ANL carries a Unified Composite Score of 48.3/100 (HOLD) at $9.97 (N/M Forward P/E, -123.5% operating margin), whereas TYRA carries 33.0/100 (SELL) at $19.77 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ANL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.0); meanwhile TYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANL leads the Growth & Scale pillar: ANL posts +178.1% YoY revenue growth and +0.0% YoY earnings growth on $18M TTM revenue (100.0% gross margin, -123.5% operating margin), compared with TYRA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ANL generates $18M in USD-normalized revenue versus N/A for TYRA. In operating R&D and SG&A reinvestment, ANL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TYRA.

ANL screens cheaper on headline valuation multiples. ANL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 37.5x EV/Revenue (-119.9% EBITDA margin), whereas TYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANL (-20.2% ROE) versus TYRA (-34.9% ROE) capital efficiency.

In options market volatility and institutional positioning, ANL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.61β · 79% Vol realized risk). By comparison, TYRA carries 69.0% implied volatility (3rd %ile, Compressed (<25th %ile)), a 12.00x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.79β · 49% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.